Embodiments of the present invention belong to the technical field of biomedicine, and specifically relate to a balasubramide derivative and use thereof in preparation of a medicine for treating acute lung injury. According to the embodiments of the present invention, it is proven through experiments that the balasubramide derivative can significantly reduce the expression of TNF-α in a macrophage cell line inflammation model, has no obvious toxicity at an effective dose, and has high safety. Moreover, the balasubramide derivative (+) 3C-20 can significantly relieve sepsis or acute lung injury induced by lung exposure to bacterial endotoxin, achieves the effect of relieving the acute lung injury of mice by inhibiting the expression of inflammatory factors in macrophages, and significantly improves the survival rate of model mice with acute lung injury.
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61P 11/00 - Drugs for disorders of the respiratory system
2.
BALASUBRAMIDE DERIVATIVE AND USE THEREOF IN PREPARATION OF DRUG FOR TREATING ACUTE LUNG INJURY
The present application relates to a balasubramide derivative and a use thereof in preparation of a drug for treating acute lung injury. Experiments prove that the balasubramide derivative can significantly reduce the expression of TNF-α in a macrophage cell line inflammation model, has no obvious toxicity under an effective dose, and has high safety; additionally, the balasubramide derivative (+)3C-20 can significantly relieve sepsis or acute lung injury induced by lung exposure to bacterial endotoxin. By inhibiting the expression of inflammatory factors in macrophages, the effect of ameliorating acute lung injury of mice is achieved, thereby significantly increasing the survival rate of model mice with acute lung injury.
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
3.
PHARMACEUTICAL USE OF TROPIC ACID AND DERIVATIVES THEREOF IN PREPARATION OF DRUG FOR TREATING IMMUNE- AND INFLAMMATION-RELATED DISEASES
The present invention belongs to the technical field of medicines, and particularly relates to the use of tropic acid and derivatives thereof in the preparation of a drug for treating immune- and inflammation-related diseases, and a drug for treating immune- and inflammation-related diseases. The tropic acid and derivatives thereof are compounds of formulae I-IV or pharmaceutically acceptable salts thereof, and solvates, esters, enantiomers, diastereomers and tautomers of said compounds or pharmaceutically acceptable salts thereof, or mixtures of any proportion of same, including racemic mixtures. Animal tests show that tropic acid and the derivatives thereof have broad-spectrum immunoregulation, anti-inflammatory and analgesic effects, have obvious improvement effects on pathologic indices of a plurality of immune- and inflammation-related disease animal models, can regulate abnormal immune responses towards being normal, and achieve good anti-inflammatory and analgesic effects. The present invention can adapt to patients suffering from different types of immune- and inflammation-related diseases having different disease levels and is industrially applicable.
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
C07C 59/52 - Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
4.
USE OF TROPIC ACID AND DERIVATIVE THEREOF IN PREPARATION OF DRUG FOR TREATING PSORIASIS
The use of tropic acid and a derivative thereof in the preparation of a drug for treating psoriasis. It is found that tropic acid and the derivative thereof can significantly improve skin damage of a psoriasis animal model. The tropic acid and the derivative thereof have low toxicity, fast action, a short treatment course, a small dosage, a low recurrence rate and is convenient to use, and the dosage forms for external use, oral administration, injection, etc. are taken into consideration, such that it is possible to adapt to patients with different degrees and different types of psoriasis. It is also found that compounds III and IV obtained by means of structural modification have a significantly better therapeutic effect than tropic acid. The small molecule drugs used are easily obtained, have a low price and stable properties, are convenient to store and transport, and have broad application prospects.
C07C 59/52 - Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
5.
AS1411 OLIGONUCLEOTIDE COMPOSITE RUTHENIUM COMPLEX NANOPROBE, AND PREPARATION METHOD AND USE THEREOF
The present disclosure provides an AS1411 oligonucleotide composite ruthenium complex nanoprobe, and a preparation method and use thereof, and belongs to the technical field of nanoprobes. In the present disclosure, the AS1411 oligonucleotide having the G-quadruplex conformation has a stable structure and can specifically bind with a nucleolin on the membrane of a tumor cell; and RuPEP, the ruthenium complex having the structure of formula 1, has excellent luminescence performance and can be used as a phosphorescent probe to highlight the tumor cell. The AS1411 oligonucleotide composite ruthenium complex nanoprobe provided by the present disclosure has a good property of entering a cancer cell, and can be used as a cancer diagnosis reagent to selectively identify and activate the transportation of an NCL receptor on a surface of the cancer cell to a nucleus, thereby promoting the imaging of the cancer cell.
Disclosed in the present invention are a system for comprehensively evaluating a glycolipid metabolic level and the use thereof, belonging to the field of disease-health state evaluation. The present invention provides a system for comprehensively evaluating a glycolipid metabolic level, comprising an input module and a comprehensive evaluation module; the input module is used for inputting glycolipid metabolic level evaluation indexes, the glycolipid metabolic level evaluation indexes comprising a waistline, fasting plasma glucose, total serum cholesterol and serum low-density lipoprotein cholesterol; the comprehensive evaluation module is used for calculating glycolipid indexes and outputting an evaluation result. The system can comprehensively analyze the body glycolipid metabolic conditions, evaluate the overall states of glycolipid metabolic diseases, and fill in the blank of glycolipid metabolic disease evaluation systems, contributing greatly to the modernization development of traditional Chinese medicine.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
7.
CHITOSAN OLIGOSACCHARIDE ENTERIC CAPSULE, AND PREPARATION METHOD THEREFOR AND USE THEREOF
Disclosed in the present invention is a chitosan oligosaccharide enteric capsule, which comprises a content and a capsule shell, wherein the content comprises an enteric excipient, chitosan oligosaccharide and a release regulator, and the mass ratio of the enteric excipient to the chitosan oligosaccharide to the release regulator is (3-5):1:1. Compared with traditional preparation processes, the preparation of the content of a chitosan oligosaccharide enteric capsule by means of a freeze-drying method in the present invention has the following characteristics of the amount of an excipient being able to be reduced to a great extent, the process being reasonable and stable, and the odor of chitosan oligosaccharide being able to be effectively masked to improve the compliance of patients. The chitosan oligosaccharide enteric capsule has the characteristics of "gastric insolubility while rapid dissolution in intestine" of enteric preparations, can effectively mask the odor of chitosan oligosaccharide to improve the compliance of patients, and can reduce the degradation of chitosan oligosaccharide in gastric acid and increase the release and absorption of the prototype of the chitosan oligosaccharide molecule in the intestinal tract.
A chitosan oligosaccharide enteric dripping pill and an application thereof in preparing a non-alcoholic fatty liver disease drug. The chitosan oligosaccharide enteric dripping pill is composed of an enteric coating and a pill core according to a mass ratio of 6-10: 13-17. The chitosan oligosaccharide enteric dripping pill can improve the abnormal lipid metabolism caused by the blood glucose level and a high-fat and high-sucrose diet, improve the abnormal indexes of liver function caused by a high-fat and high-sucrose diet, enhance the serum anti-oxidation function of mice with the non-alcoholic fatty liver disease, and promote the release of anti-inflammatory factors, thereby reducing inflammation.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
9.
APPLICATION OF GLUCOSAMINE IN PREPARATION OF NON-ALCOHOLIC FATTY TREATMENT DRUGS
The application of glucosamine in the preparation of drugs for the treatment of non-alcoholic fatty liver disease and diabetes. Experiments have proven that glucosamine at a daily dose of 300-600 mg/kg can improve insulin resistance, glycolipid metabolism disorder, and liver lipid accumulation in mice with non-alcoholic fatty liver disease, improve abnormal liver function, enhance antioxidant capacity, and reduce body inflammation and serum endotoxin levels, and thus show that glucosamine has a certain therapeutic effect on non-alcoholic fatty liver disease.
A61K 31/7008 - Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 5/50 - Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
The present invention provides a chitosan oligosaccharide composition, mainly comprising chitosan oligosaccharide, an antioxidant, an osmotic pressure regulator, a pH regulator and the like, wherein the chitosan oligosaccharide is composed of chitosan oligosaccharide 1000 (COST) and chitosan oligosaccharide 3000 (COSM). The composition of the present invention is in the form of an injection, a preparation process is simple, and industrial production is facilitated. The chitosan oligosaccharide composition provided in the present invention can significantly reduce the increase of ALT and AST when acetaminophen induces liver injury, and can reduce MDA and increase GSH content, indicating that COST and COSM can reduce oxidative injury; in addition, the content of liver antioxidant enzyme, comprising SOD, GSH-Px, and CAT, can be significantly increased, indicating that the oxidation resistance of the liver can be improved by the composition.
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
11.
CHITOOLIGOSACCHARIDE ORAL LIQUID AND APPLICATION THEREFOR IN PREPARATION OF WEIGHT LOSS DRUGS
A chitooligosaccharide oral liquid and an application therefor in the preparation of weight loss drugs, the oral liquid comprising the following raw ingredients in parts by weight: 30-45 parts of chitooligosaccharides, 1-2 parts of preservative, 0.5-1.5 parts of buffering agent, 1-3 parts of flavouring agent, and 5-8 parts of stabilising agent. The chitooligosaccharide oral liquid is safe and effective, has quick absorption, rapid effects, a stable formulation, stable quality and curative effects, and is suitable for industrial production.
2(DPPZ′). DPPZ′ is a main ligand having structural formula of
1 is C1-C5 chain alkyl group; L is an auxiliary ligand with N as coordinating atom. Sonogashira coupling reaction is utilized to introduce alkynyl group into a DPPZ-type Ruthenium complex; the introduced alkynyl group is beneficial to promote the transmembrane absorption of drug molecules, increase the probability of drug entry into cells, and can also increase efficacy and reduce toxic and side effects of drugs. The Ruthenium complex provided has significant anti-tumor activity, especially anti-breast cancer activity, and can provide new ideas for designing anti-tumor drug molecules in the future.
Provided are a whitening, acne-removing, blackhead-removing and anti-aging composition, and a use and a preparation thereof. The composition has the effects of whitening, acne-removing, blackhead-removing and anti-aging, can inhibit the expression of inflammatory factors IL-1 and TNF-a, reduce the effects of androgen dihydrotestosterone, and has the advantages of no drug resistance and no side effects when compared with hormone therapy.
A method of treating diabetes includes the step of preparing Acanthopanax trifoliatus polysaccharide ATP1-1 into drugs for treating the diabetes. The Acanthopanax trifoliatus polysaccharide ATP1-1 can alleviate the symptoms of weight loss in diabetic mice and facilitate the weight increase of mice; ATP1-1 has a hypoglycemic effect on the diabetic mice, and can enhance the ability to control blood glucose, reduce blood glucose fluctuation, and achieve the effect of treating diabetes; ATP1-1 can effectively reverse the decrease of insulin caused by injury of pancreatic islet; ATP1-1 has various degrees of therapeutic effects on mice pancreatic islets and can inhibit apoptosis of pancreatic islet cells; ATP1-1 can effectively repair injury of a spleen and regulate the body's immunologic function.
A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
15.
S,SE-CQDS AND METHOD THEREFOR FOR EFFICIENTLY DETECTING CR(VI) CONTAMINANT
ZHONGHE SANNONG (GUANGDONG) GROUP CO., LTD. (China)
Inventor
Liu, Yi
Luo, Yufeng
Chen, Ping
Pan, Miaochuan
Abstract
S,Se-CQDs and a method therefor for efficiently detecting Cr(VI) contaminant, which relate to the cross-over field of nanometer new materials and environmental analysis. The method comprises: dissolving citric acid, mercaptoethylamine and sodium selenite in pure water, naturally reducing the temperature to room temperature after the hydrothermal reaction, extracting and centrifuging the solvent, separating the supernatant, dialyzing and freeze-drying the supernatant, and preparing doped carbon quantum dots S,Se-CQDs having a high fluorescence intensity. Said method for preparing S,Se-CQDs has a simple process and is low-cost, and the S,Se-CQDs prepared can efficiently detect Cr(VI); the fluorescence of the "Cr(VI)+S,Se-CQD" system can be recovered by 80% after adding a suitable amount of vitamin C(Vc); and the method for detecting Cr(VI) by S,Se-CQDs is simple and low-cost, has an obvious selection difference and a strong anti-interference capability.
A novel PPAR γ/δ dual agonist as described in general formula (I), a preparation method thereof and an application of a pharmaceutical composition containing a derivative in the preparation of a drug for prevention and/or treatment of disorders of glucose metabolism and/or disorders of lipid metabolism. The PPAR γ/δ dual agonist has in vivo activity of lowering blood sugar, regulating blood lipids and preventing fibrosis, and may be used in the preparation of a drug for the prevention and/or treatment of illnesses related to metabolic syndromes such as diabetes mellitus, obesity, hyperlipidemia, atherosclerosis, fibrosis and fatty liver.
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
17.
NOVEL PHENYLACETIC ACID DERIVATIVE, PREPARATION METHOD THEREOF AND USE THEREOF AS DRUG
The present invention relates to a novel deuterated 3-pentylphenylacetic acid derivative represented by general formula (I), a preparation method thereof, and a use of a pharmaceutical composition containing the derivative in preparation of a drug for preventing or/and treating organ fibrosis-associated diseases. The compound of the present invention has more excellent drug metabolism properties and anti-organ fibrosis effect in vivo, and can be applied to the preparation of drugs for preventing and/or treating fatty liver, hepatic fibrosis, pulmonary fibrosis, renal fibrosis, cardiac fibrosis, Alström syndrome and other organ fibrosis associated diseases, and has a wide application prospect.
Application of an acanthopanax trifoliatus polysaccharide ATP1-1 in the preparation of medicines for treating diabetes. The ATP1-1 is capable of alleviating the symptom of weight loss in diabetic mice, and promoting weight gain of the mice. The ATP1-1 has blood glucose reduction effects on diabetic mice, and may enhance control capabilities over blood glucose and decrease fluctuation of blood glucose. The ATP1-1 may effectively reverse insulin reduction caused by islet damage, may inhibit apoptosis of islet cells, may effectively repair spleen injury, and regulate immune functions of the body.
A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
19.
SMALL MOLECULE FLUORESCENT AGENT AND PREPARATION METHOD THEREOF
Provided by the present invention is a small molecule fluorescent agent. The structure of the small molecule fluorescent agent is represented by formula I. Further provided by the present invention is a method for preparing the small molecule fluorescent agent, which comprises the following steps: adding citric acid, chlorophyll and mercaptoethylamine to an ethanol aqueous solution in sequence, stirring to dissolve and then adding a nucleation inducer, and after continuing to stir evenly, the mixture undergoing a hydrothermal reaction to obtain a product. The small molecule fluorescent agent of the present invention is a high-efficiency blue-light fluorescent agent having a brand-new structure, and which has high-efficiency fluorescence characteristics and emits blue fluorescence under the action of an excitation light having a wavelength of 365 nm. In addition, the preparation method of the present invention adopts a one-step method, so the process is simple, the reaction selectivity is high, the yield is high, and the production costs are low.
C07D 207/333 - Radicals substituted by oxygen or sulfur atoms
C07D 487/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains four or more hetero rings
Disclosed is the use of a chitosan oligosaccharide (COSM) with a molecular weight less than or equal to 3000 in the preparation of a composition for protecting and treating drug-induced liver injury. In particular, the use thereof in the preparation of a composition for protecting and treating acetaminophen-induced liver injury is disclosed. Further disclosed is a method for protecting and treating drug-induced liver injury, the method comprising administering an effective amount of a COSM to a subject with liver injury. Experiments prove that the COSM can regulate abnormalities of biochemical indicators of liver function induced by acetaminophen; significantly reduce the abnormal elevation of ALT and AST in mouse serum induced by acetaminophen; improve liver tissue injury induced by acetaminophen; increase the content of glutathione (GSH), a detoxicant, in liver tissue affected by acetaminophen-induced liver injury; increase the oxidation resistance of liver affected by acetaminophen-induced oxidative injury; and reduce the content of malondialdehyde (MDA) of acetaminophen-induced liver oxidative injury. The COSM is expected to be developed and applied to treating liver injury caused by clinical treatment drugs, which provides a better choice for patients.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
21.
USE OF CHITOOLIGOSACCHARIDES FOR PROTECTING AGAINST AND TREATING DRUG-INDUCED LIVER INJURY
Disclosed is a use of chitooligosaccharides (COST) having a molecular weight of ≤1000 in the preparation of a composition for protecting against and treating drug-induced liver injury, particularly a composition for protecting against and treating liver injury induced by acetaminophen. Also disclosed is a method for protecting against and treating drug-induced liver injury, comprising administering an effective amount of COST to a subject having a liver injury. Experiments confirmed that COST improved abnormal biochemical indices of liver function induced by acetaminophen, significantly reduced an abnormal increase in mouse serum ALT and AST induced by acetaminophen, ameliorated liver tissue injury induced by acetaminophen, increased an amount of glutathione (GSH) as a detoxicant in a liver tissue having acetaminophen-induced liver injury, increased an anti-oxidation ability of oxidatively damaged liver induced by acetaminophen, and decreased an amount of malondialdehyde (MDA) in oxidatively damaged liver induced by acetaminophen. The present invention can enable treatment of a clinical drug-induced liver injury, offering a better option for patients.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
22.
Biomass-based high-efficiency fluorescent graphene quantum dot and preparation method thereof
The invention relates to the field of nano materials, in particular to biomass-based high-efficiency fluorescent graphene quantum dot and preparation method thereof. Method for preparing biomass-based high-efficiency fluorescent graphene quantum dots includes hydrothermal reaction of composite carbon source, nitrogen source, polyvalent metal ion and water. The method for preparing a biomass-based high-efficiency fluorescent graphene quantum dot includes the following steps: (1) Mixing the composite carbon source and the nitrogen source, and then adding water, stirring and dissolving to obtain a mixture A; (2) Adding polyvalent metal ions to the mixture A, and after stirring, heating and reacting to obtain a crude product; (3) The crude product is purified by dialysis to obtain a purified product. The biomass-based high-efficiency fluorescent graphene quantum dot of the invention has the characteristics of high fluorescence intensity, high yield, simple preparation method and wide range of application.
The present invention relates to a medical use of quercetin in prevention and treatment of drug-induced acute liver injury, and in particular, to application of the quercetin in preparation of a drug for prevention and treatment of liver injury caused by acetaminophen. Animal experiments prove that the quercetin controls abnormal rise in biochemical indicators related to acetaminophen-induced liver functions and changes in pathological structures, and increases the content of in-vivo antidote GSH in acetaminophen-induced liver tissue injury; the quercetin is an oral preparation or injection preparation, the administration dosage may be changed according to the age, the weight, the intake amount of acetaminophen, the arrangement of a treatment course and the like of a patient, a recommended administration dosage for a person is 40 mg/kg/d, and an oral administration mode is recommended; the quercetin can effectively resist liver injury caused by acetaminophen, and can be used for preparing a drug for treating liver injury caused by acetaminophen.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
24.
USE OF ORAL PREPARATION OF JINQI JIANGTANG IN PREPARATION OF DRUG FOR ULCERATIVE COLITIS
Use of an oral preparation of Jinqi Jiangtang in preparation of a drug for ulcerative colitis. Oral preparation of Jinqi Jiangtang applied in animal experiment and clinical application have returned no reports of toxication, thereby proving that the oral preparation of Jinqi Jiangtang is safe and non-toxic. Moreover, the resource for the material of the oral preparation is abundant. The invention can be further developed for use in drugs inhibiting inflammation, and has good potential for clinical application and economic prospects.
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
The present invention belongs to the field of use of organic compounds, and specifically to use of a 6-fluoroimidazopyridine derivative. The 6-fluoroimidazopyridine derivative represented by formula (I) provided in the present invention is used for preparation of bacteria killing and inhibiting articles for daily use; the 6-fluoroimidazopyridine derivative is also applied to bacteria-inhibiting hand washing liquid; the bacteria-inhibiting hand washing liquid has multiple functions of removing stains, killing bacteria, protecting skin and inhibiting bacteria; meanwhile, the bacteria-inhibiting hand washing liquid provided in the present invention has a good allergy-resisting effect, is high in safety and also has a good application prospect.
A61Q 17/00 - Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
A use of a benzofuran derivative represented by formula I in preparing a microbicidal and anti-inflammatory commodity. Further provided is a use of the benzofuran derivative in a microbicidal and anti-inflammatory toothpaste, wherein the microbicidal and anti-inflammatory toothpaste has effects of inhibiting microbes, reducing inflammation, preventing bleeding gums, improving the oral environment, and easing pain without added hormone drugs.
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A long-acting antibacterial band-aid, comprising an adhesive tape layer (1), a sponge layer (3) composed of chitosan and cellulose, and a porous drug layer composed of 6,6'-difluoro-3,3'-biimidazo[1,2-a]pyridine and 5-hexanoyl-2-methyl-N-o-tolyl-3-carboxamide, the sponge layer (3) being located between the adhesive tape layer (1) and the porous drug layer (2). The band-aid comprises a porous drug layer (2), and the contained drugs may effectively inhibit the proliferation of bacteria, while blood and tissue fluid at a wound may enter the sponge layer (2) by means of small pores while the drugs are released; meanwhile, the sponge layer (2) may quickly absorb blood and tissue fluid, has an antibacterial effect, may better maintain a sterile environment, and promotes the healing of a wound.
The present invention relates to the technical field of macromolecule measurement, and relates to a method for measuring the content of chitosan oligosaccharide. According to the present invention, a phenol-fluorescence spectrophotometry is used, after chitosan oligosaccharide is mixed with a phenol solution, the amino group of chitosan oligosaccharide is bound with the hydroxyl group of phenol, so that the pH value of the mixed aqueous solution is changed, and fluorescence quenching occurs to the phenol, resulting in exponential fall in fluorescence intensity, so that the concentration of the chitosan oligosaccharide is in a linear relationship with a fluorescence log value within a certain range, so as to measure the content of the chitosan oligosaccharide. The method has low costs, high sensibility, high stability and good reproducibility, the concentration measurement range is 0 to 2.4 mg/ml, the method is widely used, can be used for measuring the contents of chitosan oligosaccharide in different dosage forms, and solves the problems in the prior art of complex operations, high costs, low accuracy, and a small measurement range.
The present invention belongs to the technical field of oligosaccharide production, and particularly relates to a method for preparing a chitooligosaccharide using snailase and application thereof. The method for preparing a chitooligosaccharide using snailase involves increasing enzymatic efficiency by exploring and optimizing specific process conditions for enzymolysis of chitosan by snailase, such as enzymolysis time, enzymolysis temperature, substrate concentration, mass ratio of enzyme to substrate, etc., and involves maintaining properties of the chitooligosaccharide by means of freeze drying, so as to facilitate product preservation and further product use. The method provides a basis for mass production of a chitooligosaccharide using snailase. The chitooligosaccharide prepared has a good ameliorating effect on idiopathic pulmonary fibrosis, as indicated by significantly improved fibroblast activation in a rat model of idiopathic pulmonary fibrosis, and thus will be conducive to the rehabilitation of a patient with idiopathic pulmonary fibrosis.
A chitosan oligosaccharide prepared by a compound enzyme and a preparation method for the chitosan oligosaccharide. The preparation method comprises the following steps: dissolving chitosan into an acetic acid-sodium acetate buffer solution; then adding a compound enzyme solution into the chitosan solution for enzymolysis; after the enzymolysis is finished, dialyzing filtrate by adopting a dialysis method after filtering the obtained enzymolysis solution; finally concentrating and drying the obtained dialysis solution to obtain the chitosan oligosaccharide. The chitosan oligosaccharide is small in molecular weight, concentrated in degree of polymerization and high in yield, and is applicable to the fields of medicines, foods, cosmetics and the like; moreover, the preparation method is simple in operation and low in material costs.
A low molecular weight chitooligosaccharide and a preparation method therefor, comprising the steps of dissolving chitosan in an acetate-sodium acetate buffer solution, preparing a chitosan solution, adding a compound enzyme solution into the chitosan solution for enzymatic digestion, dialyzing a filtrate by using dialysis after the completion of enzymatic digestion, concentrating an obtained dialysate and then spray-drying, and so on. The described preparation method has the advantages of the yield of low molecular weight chitooligosaccharide being high, conditions being simple, time required for preparation being short, the enzymes used being cheap and easy to obtain, and production costs being low, thus being suitable for wide-scale promotion and application.
The present invention discloses a method for preparing a nanocomposite of an arene-ruthenium complex and a nucleic acid, and also relates to a nanocomposite of an arene-ruthenium complex and a nucleic acid, and a use thereof in the preparation of an anti-neoplastic agent. The method for preparing a nanocomposite of an arene-ruthenium complex and a nucleic acid provided by the present invention is simple and involves mild preparation conditions, allowing for fast and convenient preparation of the target nanocomposite. The nanocomposite of an arene-ruthenium complex and a nucleic acid prepared by the method according to the present invention has excellent anti-neoplastic activity and the advantages of being highly targeted and less toxic. Therefore, the nanocomposite of an arene-ruthenium complex and a nucleic acid is suitable for preparing a variety of anti-cancer agents or DNA/RNA intercalating agents, and thus has broad clinical application.
Provided is a method for preparing chitosan oligosaccharide by using a lipase. The method comprises dissolving chitosan in an acetic acid-sodium acetate buffer solution and adding sucrose fatty acid ester to prepare a chitosan solution, adding a lipase to the chitosan solution for enzymatic hydrolysis, dialyzing an enzymatic hydrolysate after the enzymatic hydrolysis, and concentrating the resulting dialysate and drying.
Provided are an amino-substituted indolizine compound having anticancer activity and a derivative thereof. Said compound and derivative thereof as shown in formula (I) have an inhibitory effect on a plurality of cancers and tumors.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A sulfonyl substituted furan compound having anti-inflammatory immune activity and a derivative thereof, represented by the following formula (I):. The compound and a derivative thereof have anti-inflammatory immune activity.
C07D 207/333 - Radicals substituted by oxygen or sulfur atoms
C07D 209/10 - Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
C07D 307/38 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
C07D 307/79 - Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
A61K 31/34 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61P 37/00 - Drugs for immunological or allergic disorders
36.
INDOLIZINE COMPOUND HAVING ANTICANCER ACTIVITY AND DERIVATIVE THEREOF
Provided are an indolizine compound having anticancer activity and a derivative thereof. Said compound and derivative thereof as shown in formula (I) have an inhibitory effect on a plurality of tumors.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
37.
THIOLIZED INDOLIZINE COMPOUND HAVING ANTICANCER ACTIVITY AND DERIVATIVE THEREOF
Probided are a hiolized indolizine compound having anticancer activity and a derivative thereof. Said compound and derivative thereof shown in formula (I) have an inhibitory effect on a purality of cancers and tumors.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
Provided are chitosan oligosaccharide granules and a preparation method therefor. The chitosan oligosaccharide granules comprise chitosan oligosaccharides, anhydroicaritin, povidone and aspartame, and are prepared with the following method: adding chitosan oligosaccharides, anhydroicaritin and aspartame into a configured anhydrous ethanol solution of povidone, stirring uniformly, and finally granulating the mixture.
A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
A61K 31/7016 - Disaccharides, e.g. lactose, lactulose
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
The present invention provides a chitosan oligosaccharide oral solution and a preparation method therefor. The chitosan oligosaccharide oral solution comprises 25-40 parts of chitosan oligosaccharides, 1-3 parts of a flavoring agent, 2-4 parts of a preservative, and 1.5-2 parts of a stabilizer. The chitosan oligosaccharide oral solution of the present invention significantly improves the stability of the chitosan oligosaccharide liquid preparation and improves the taste of chitosan oligosaccharides. The chitosan oligosaccharide oral solution of the present invention has good stability and good taste, and has remarkable weight loss effect.
A chitosan oligosaccharide dropping pill and a preparation method therefor. The chitosan oligosaccharide dropping pill is prepared from chitosan oligosaccharides and a dropping pill matrix, the weight ratio of the chitosan oligosaccharides to the dropping pill matrix being 1:1 to 1:5. The dropping pill formulation of the present invention can significantly improve the dissolution and stability of chitosan oligosaccharides.
Disclosed are a chitosan dropping pill and a preparation method therefor. The chitosan dropping pill is prepared from chitosan and a dropping pill matrix, and the weight ratio of each ingredient is: chitosan : dropping pill matrix = 1:1-1:6. The formulation of the dropping pill preparation is determined by scientific screening tests. The preparation can significantly increase the dissolution of chitosan and improve the bioavailability thereof. The chitosan dropping pill is simple in preparation process and low in cost, and has good application prospects.
Provided in the present invention are a chitosan oral solution and a preparation method therefor. The chitosan oral solution comprises 6-12 parts by weight of chitosan; 0.5-3.5 parts by weight of a solubiliser; and 0.1-0.5 parts by weight of a preservative.
A chitosan composition and a preparation method therefor. Said composition consists of chitosan, L-carnitine tartrate, a Phaseolus vulgaris extract and a ginsenoside extract, and has significant weight loss and hypoglycemic effects. Said composition is safe and non-toxic, and the preparation method therefor is simple in process, convenient to operate and saves energy.
Disclosed are a composition for reducing weight and lowering glucose and lipids, a preparation method therefor and a use thereof, wherein the raw materials of the composition are: chitosan oligosaccharide, metformin hydrochloride, Garcinia cambogia extracts, cactus extracts and Celosiae semen extracts.
Provided is an alkynyl-containing ruthenium complex, and also involved are a method for synthesizing the alkynyl-containing ruthenium complex and the use thereof. The alkynyl-containing ruthenium complex is a new type of ruthenium complex, and an alkynyl is introduced into the DPPZ-type ruthenium complex by means of the Sonogashira coupling reaction. The introduced alkynyl is favorable for promoting the transmembrane absorption of drug molecules, improves the probability of drugs entering cells, and can also enhance the pharmaceutical efficacy and lower the toxicity and side effects of the drugs. The alkynyl-containing ruthenium complex provided in the invention has a significant anti-tumor activity, in particular an anti-breast cancer activity, and at the same time, provides a new idea for the design of future anti-tumor drug molecules. The alkynyl-containing ruthenium complex provided in the invention can also be used as a fluorescent probe. In a word, the alkynyl-containing ruthenium complex has broad prospects for use in the field of medicinal chemistry.
Disclosed is a hepatoma cell-targeting antimicrobial peptide chimera M27-39-HTPP and the use thereof, wherein same is obtained by the fusion of positions 27 to 39 of Musca domestica cecropin with a hepatocyte-targeting and penetrating peptide (HTPP), the amino acid sequence of which is as shown in SEQ ID NO: 1. The present invention uses a solid phase chemical synthesis method to obtain the crude M27-39-HTPP targeting antimicrobial peptide chimera, and uses reverse-phase high performance liquid chromatography and electrospray mass spectrometry to purify and identify the synthesized polypeptide. The hepatocyte-targeting M27-39-HTPP has a targeted anti-liver cancer effect, and has great practical significance and broad application prospects in the fields of medicine and bio-pharmacy, especially in the field of the preparation of anti-hepatoma drugs.
An endotracheal tube loaded with antimicrobial peptide MDC coating and a preparation method therefor and an application thereof. The endotracheal tube uses antimicrobial peptide MDC as the antibacterial agent and uses chitosan gel as the fixing and slow-release substrate to perform surface coating on the endotracheal tube to make an endotracheal tube loaded with antimicrobial peptide MDC coating. The antimicrobial peptide MDC sequence is shown as SEQ ID NO:1. The endotracheal tube loaded with antimicrobial peptide MDC coating has significant antibiotic properties and can effectively prevent colonization and growth of the bacteria. Therefore, when the endotracheal tube loaded with antimicrobial peptide MDC coating is applies to artificial tracheal intubation and ventilator, the occurrence of tracheal intubation ventilator-associated pneumonia can be decreased or delayed, the medical economic burden can be reduced, and the patient's physical and mental pain can be relieved. Thus, the prospect is vast.
The present invention belongs to the field of oligosaccharide preparation, and relates in particular to a method for preparing chitosan oligosaccharide by means of papain freeze drying. The method for preparing chitosan oligosaccharide by means of papain freeze drying comprises steps such as dissolving chitosan in an acetic acid-sodium acetate buffer solution to prepare a chitosan solution, adding a papain solution to the chitosan solution for enzymolysis, performing dialysis on a filtrate by means of a dialysis method after the enzymolysis has finished, heating and concentrating a collected dialysate, and freeze drying. The method for preparing chitosan oligosaccharide by means of papain freeze drying is simple, rapid, efficient and suitable for industrial production, and has good practicality and value for promotion in industry.
A method for preparing chitosan oligosaccharide by means of cellulase spray drying, said method comprising: preparing a chitosan solution, adding a cellulase solution for enzymolysis, performing dialysis, concentrating, and spray drying. The method has mild conditions, is simple to perform, takes a small amount of time, uses cellulase which is inexpensive and readily available, and has low production costs. The obtained chitosan oligosaccharide has uniform molecular weight distribution and colour.
Dryopteris fragransDryopteris fragrans phloroglucinol compound flavaspidic acid BB. The present invention provides for the first time a method of chemical synthesis to obtain a flavaspidic acid BB compound, which has good antibacterial applications and effectively remedies shortcomings in the application of natural antibacterial compounds, and particularly provides an effective antibacterial solution for drug-resistant bacteria. Experimental results showed that the compound obtained by the present invention has strong antibacterial effects, especially exhibiting good curative effects against drug-resistant bacteria.
An application of bilobalide as a synergist in preparation of drugs or health-care products for preventing cranial nerve injury diseases. Bilobalide and hydroxyl derivatives thereof can promote various drugs with a therapeutic or health-care function on cranial nerve injury diseases to enter brain tissues, including ginsenoside, stibene glucoside, resveratrol, levodopa, edaravone, vinpocetine, nicergoline, citicoline, oxiracetam and the like. The efficacy of the drugs can be improved, and side effects and adverse reactions of the drugs can be reduced.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 25/00 - Drugs for disorders of the nervous system
A61K 31/198 - Alpha-amino acids, e.g. alanine, edetic acid (EDTA)
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/48 - Ergoline derivatives, e.g. lysergic acid, ergotamine
A61K 31/7028 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
A61K 31/4152 - 1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
53.
METHOD FOR MEASURING DEGREE OF DEACETYLATION OF CHITOSAN OLIGOSACCHARIDE BY USING FIRST-ORDER DERIVATIVE ULTRAVIOLET SPECTROPHOTOMETRY
A method for measuring the degree of deacetylation of a chitosan oligosaccharide by using first-order derivative ultraviolet spectrophotometry, comprising the steps of 1) with a hydrochloric acid solution having a concentration of 0.3-1.0 mol/L as a blank solvent, preparing standard solutions of N-acetyl-D-glucosamine at a series of concentrations, measuring the ultraviolet absorbance values A of the standard solutions of N-acetyl-D-glucosamine within a wavelength range of 200-206 nm, and plotting a standard curve according to the concentrations of N-acetyl-D-glucosamine and ΔA/Δλ; and 2) dissolving a chitosan oligosaccharide sample with the blank solvent, with the blank solvent as a reference, measuring the absorbance value of the chitosan oligosaccharide sample at a wavelength of 200-206 nm, and calculating the degree of deacetylation of the chitosan oligosaccharide sample according to the standard curve.
G01N 21/33 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using ultraviolet light
54.
PROCESS FOR MEASURING DEGREE OF DEACETYLATION OF CHITOSAN OLIGOSACCHARIDE USING ACID-BASE INDICATOR METHOD
A process for measuring the degree of deacetylation of a chitosan oligosaccharide using an acid-base indicator method, comprising the steps of S1. measuring the content of water in a chitosan oligosaccharide sample, as a reduced weight under dry weight loss item of the chitosan oligosaccharide sample; S2. weighing a chitosan oligosaccharide sample, dissolving the sample with distilled water, adjusting the pH to 8.0, adding a dilute hydrochloric acid titrant while adding 1-2 drops of a 1% bromocresol green indicator, and after uniform mixing, titrating the solution with a sodium hydroxide titrant until the solution becomes green, i.e. reaching the titration end point; and S3. calculating the degree of deacetylation of the chitosan oligosaccharide sample. The method is an accurate, rapid method for measuring the degree of deacetylation of a chitosan oligosaccharide; moreover, the instruments used are simple, the operation is simple, no special sample pretreatment is required, the titration end point is obviously determined, the measurement error is small, and the method is suitable for the quality control in the process of the preparation of a chitosan oligosaccharide.
The present disclosure belongs to the technical field of pharmaceutical preparations and specifically relates to a chitosan oligosaccharide capsule and method for preparation thereof. The chitosan oligosaccharide capsule comprises content and a capsule shell; said content consists primarily of chitosan oligosaccharide, microcrystalline cellulose, adhesive, calcium stearate, ethanol, and micropowder silicone; said capsule shell consists primarily of hydroxypropyl starch, xanthan gum, thickener, plasticizer, and water. The chitosan oligosaccharide capsule is odorless, has a neat appearance, and is smooth; its content uniformity and solubility satisfy the relevant provisions of the Pharmacopoeia of China, and the capsule has relatively good sealing tightness and resistance to oxidation; it effectively addresses the problem of chitosan oligosaccharide being prone to oxidation and moisture absorption, facilitating the long-term storage of chitosan oligosaccharide.
C12P 1/02 - Preparation of compounds or compositions, not provided for in groups , by using microorganisms or enzymes; General processes for the preparation of compounds or compositions by using microorganisms or enzymes by using fungi
58.
PREPARATION AND APPLICATION OF FLAVONOL AS BRAIN-TARGETING SYNERGIST
The present application provides a preparation and application of flavonol as a brain-targeting synergist. The flavonol is selected from kaempferide, rutin, troxerutin, myricetin, hesperidin and derivatives thereof. The flavonol is capable of improving the concentration of a medicine in brain tissues and improving the efficacy of the medicine. The medicine is selected from ginsenoside, stilbene glucoside, resveratrol, levodopa, edaravone, vinpocetine, nicergoline, citicoline and oxiracetam.
A61K 31/7084 - Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/7034 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
A61K 31/4152 - 1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
59.
A CLASS OF NEW TYPE GROWTH HORMONE RELEASING HORMONE-LIKE PEPTIDE AND USE THEREOF IN THE PREPARATION OF A DRUG FOR TREATING INFERTILITY
Disclosed in the present invention is a class of new type growth hormone releasing hormone-like peptide. The growth hormone releasing hormone-like peptide is in the form of homodimer and has a relatively high releasing activity of pituitary GH and specificity of pituitary hormone release, which can be used to prepare a drug for treating infertility.
A61P 15/08 - Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
LONZA GUANGZHOU RESEARCH AND DEVELOPMENT CENTER LTD. (China)
Inventor
Zang, Linquan
Guo, Yanming
Chen, Liang
Abstract
Provided are a ligand having the structure of formula (I) and a complex formed by platinum and the ligand, wherein the ligand is simple in structure, capable of coupling with a variety of reagents, has a low synthesis cost and good targeting, and thus can be used for targeted therapy and diagnosis of tumours.
C07K 5/11 - Tetrapeptides the side chain of the first amino acid containing more amino groups than carboxyl groups, or derivatives thereof, e.g. Lys, Arg
C07K 1/107 - General processes for the preparation of peptides by chemical modification of precursor peptides
A traditional Chinese medicine composition for promoting nerve regeneration and the preparation method and use thereof. The traditional Chinese medicine composition consists of fleece-flower root, ginseng and ginkgo leaf; alternatively, the composition can also be composed of commercially available fleece-flower root extract, ginseng extract and ginkgo leaf extract. The preparation method for the traditional Chinese medicine composition comprises using C1-3 alcohol to extract the active pharmaceutical ingredients; concentrating; loading into a macroporous adsorption resin column; eluting with ethanol; collecting the eluate; recycling the ethanol; drying; and mixing; alternatively, recycling the ethanol, concentrating same to form a viscous plaster, drying, pulverizing, then mixing. The traditional Chinese medicine composition also treats cerebral ischemic injury, protects the nerves, improves learning and memory, and treats Alzheimer's disease.
A61K 36/16 - Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
The compound traditional Chinese medicine extract for the prevention and treatment of lipid metabolism disorders, wherein the active ingredients of the extract are composed of 1-cerotol, β-sitosterol, n-hexacosanoic acid, atractylenolide III, oleanolic acid, berberine, jateorrhizine, coptisine, tanshinol, salvianolic acid B, cyclotetracosane, 9,12-octadecadienoic acid, 5,7-dimethoxycoumarin, specnuezhenide, ginsenoside Rb1 and Rg1, notoginsenoside R1 and eucommiol. The preparative method comprises extracting crude drug Radix Salviae Miltiorrhizae, Fructus Ligustri Lucidi, Rhizoma Coptidis, Herba Cirsii Japonici, Cortex Eucommiae, Rhizoma Atractylodis Macrocephalae, Radix Notoginseng and Fructus Citri Sarcodactylis with C1-3 alcohol and/or water, combining total extracts, extracting the total extracts with different organic solvents (such as petroleum ether, ethyl acetate and n-butyl alcohol) to obtain effective part separately, and blending every effective part to obtain the product.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/047 - Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
A61K 31/045 - Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
Disclosed is a compound Chinese medicine extract used for preventing and treating arteriosclerosis, which comprises the following active components: ceryl alcohol, beta-sitosterol, hexacosanic acid, atractylenolide Ⅲ, oleanolic Acid, berberine, jatrorrhizine, coptisine, salvianic acid A, salvianolic acid B, cyclotetracosane, 9,12-linoleic acid, 5,7-dimethoxycoumarin, Specnuezhenide, ginsenoside Rb1 and Rg1, notoginsenoside R1, eucommiol, etc. The said extract is prepared from the raw medicines of danshen root, glossy privet fruit, coptis root, Japanese thistle herb or root, eucommia bark, largehead atractylodes rhizome, panax notoginseng, and bergamot, through mixing effective fractions extracted by organic solvents with different polarity from the total extract of the raw medicine which is extracted by C1-3 alcohol and/or water. Because of elimination of large quantities of noneffective components, the content of the effective components increases largely, and the influence of noneffective components to product processing and formulation quality is decreased. The preparation method is stable and available for mass production with controllable product quality.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
64.
PETROLEUM ETHER EXTRACT OF TRADITIONAL CHINESE MEDICINE FOR PREVENTION AND TREATMENT OF SUGAR AND LIPID METABOLISM DISORDERS AND PREPARATION METHOD THEREOF
The petroleum ether extract of traditional Chinese medicine for the prevention and treatment of sugar and lipid metabolism disorders, wherein the active ingredients of the extract are composed of 1-cerotol, β-sitosterol, n-hexacosanoic acid, atractylenolide III, oleanolic acid, berberine, jateorrhizine, salvianolic acid B, cyclotetracosane, 9,12-octadecadienoic acid, 5,7-dimethoxycoumarin, ginsenoside Rb1. The preparative method comprises extracting crude drug Radix Salviae Miltiorrhizae, Fructus Ligustri Lucidi, Rhizoma Coptidis, Herba Cirsii Japonici, Cortex Eucommiae, Rhizoma Atractylodis Macrocephalae, Radix Notoginseng and Fructus Citri Sarcodactylis with C1-3 alcohol and/or water, combining total extracts, extracting the total extracts with petroleum ether to obtain the petroleum ether extract.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
A61K 31/045 - Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
The compound traditional Chinese medicine extract for the prevention and treatment of glycometabolism disorders, wherein the active ingredients of the extract are composed of 1-cerotol, β-sitosterol, n-hexacosanoic acid, atractylenolide III, oleanolic acid, berberine, jateorrhizine, coptisine, tanshinol, salvianolic acid B, cyclotetracosane, 9,12-octadecadienoic acid, 5,7-dimethoxycoumarin, specnuezhenide, ginsenoside Rb1 and Rg1, notoginsenoside R1 and eucommiol. The preparative method comprises extracting crude drug Radix Salviae Miltiorrhizae, Fructus Ligustri Lucidi, Rhizoma Coptidis, Herba Cirsii Japonici, Cortex Eucommiae, Rhizoma Atractylodis Macrocephalae, Radix Notoginseng and Fructus Citri Sarcodactylis with C1-3 alcohol and/or water, combining total extracts, extracting the total extracts with different organic solvents (such as petroleum ether, ethyl acetate and n-butyl alcohol) to obtain effective part separately, and blending every effective part to obtain the product.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/047 - Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
A61K 31/045 - Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
A composition of extracts from plants which can be used for prophylaxis or treatment of metabolism disorder of blood lipid, includes the following ingredients in weight: oleanolic Acid of 3-10 portions, salvianolic acid of 1-5 portions, danshensu 1-5 portions, berberine of 1-3 portions, total saponins of panax notoginseng of 1-5 portions, polysaccharides of atractylodes macrocephala koidz of 1-5 portions, aucubin of 1-3 portions, total flavone in cirsium japonicum of 1-5 portions, bergamot polysaccharide of 1-5 portions, panax notoginseng polysaccharides of 1-5 portions, flavones of 1-5 portions. The use of such composition in manufacturing medicaments used for prophylaxis or treatment of diseases related to metabolism disorder of blood lipid. And the use of such composition in manufacturing health food used for adjuvant prophylaxis or treatment of diseases related to metabolism disorder of blood lipid.
A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 31/34 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/35 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
The chiral ruthenium complexes which having the general formula: A-[Ru(bpy)2L](PF6)2,Wherein A=△ or ∧;L=tFPIP, IPBP, IPBH or PYNI. The said complexes have apparently inhibitory activity of cell line such as BEL-7402 of hepatocellular carcinoma et al, and can be used for preparing anti-tumor drug.
patents
